These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18055238)

  • 21. 3D-QSAR studies for the binding affinity toward (R, S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor.
    Sharma RN; Thakar H; Vasu KK; Chaturvedi SC
    Acta Pharm; 2008 Sep; 58(3):335-45. PubMed ID: 19103570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors.
    Teixeira C; Barbault F; Rebehmed J; Liu K; Xie L; Lu H; Jiang S; Fan B; Maurel F
    Bioorg Med Chem; 2008 Mar; 16(6):3039-48. PubMed ID: 18226912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards predictive inhibitor design for the EGFR autophosphorylation activity.
    San Juan AA
    Eur J Med Chem; 2008 Apr; 43(4):781-91. PubMed ID: 17689836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular modeling studies on imidazo[4,5-b]pyridine derivatives as Aurora A kinase inhibitors using 3D-QSAR and docking approaches.
    Lan P; Chen WN; Chen WM
    Eur J Med Chem; 2011 Jan; 46(1):77-94. PubMed ID: 21093113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM).
    Peng T; Pei J; Zhou J
    J Chem Inf Comput Sci; 2003; 43(1):298-303. PubMed ID: 12546565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
    Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta.
    Du J; Qin J; Liu H; Yao X
    J Mol Graph Model; 2008 Sep; 27(2):95-104. PubMed ID: 18436460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
    Holder S; Lilly M; Brown ML
    Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multitemplate alignment method for the development of a reliable 3D-QSAR model for the analysis of MMP3 inhibitors.
    Tuccinardi T; Ortore G; Santos MA; Marques SM; Nuti E; Rossello A; Martinelli A
    J Chem Inf Model; 2009 Jul; 49(7):1715-24. PubMed ID: 19522467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.
    Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD
    J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME; Endicott JA; Johnson LN
    Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
    Ahmed M; Sadek MM; Abouzid KA; Wang F
    J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design of Novel Chemotherapeutic Agents Targeting Checkpoint Kinase 1 Using 3D-QSAR Modeling and Molecular Docking Methods.
    Balupuri A; Balasubramanian PK; Cho SJ
    Curr Comput Aided Drug Des; 2016; 12(4):302-313. PubMed ID: 27585602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
    Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
    J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3D QSAR studies on GSK-3 inhibition by aloisines.
    Zeng M; Jiang Y; Zhang B; Zheng K; Zhang N; Yu Q
    Bioorg Med Chem Lett; 2005 Jan; 15(2):395-9. PubMed ID: 15603961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacophore identification and validation study of CK2 inhibitors using CoMFA/CoMSIA.
    Morshed MN; Muddassar M; Pasha FA; Cho SJ
    Chem Biol Drug Des; 2009 Aug; 74(2):148-58. PubMed ID: 19563463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CoMFA and docking studies of 2-phenylindole derivatives with anticancer activity.
    Liao SY; Qian L; Miao TF; Lu HL; Zheng KC
    Eur J Med Chem; 2009 Jul; 44(7):2822-7. PubMed ID: 19167135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds.
    Srivani P; Sastry GN
    J Mol Graph Model; 2009 Feb; 27(6):676-88. PubMed ID: 19147382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New dual inhibitors of EGFR and HER2 protein tyrosine kinases.
    Fink BE; Vite GD; Mastalerz H; Kadow JF; Kim SH; Leavitt KJ; Du K; Crews D; Mitt T; Wong TW; Hunt JT; Vyas DM; Tokarski JS
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4774-9. PubMed ID: 16111887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.